CA2473990A1 - Modulation of type ii.beta. phosphoinositide phosphate kinase - Google Patents

Modulation of type ii.beta. phosphoinositide phosphate kinase Download PDF

Info

Publication number
CA2473990A1
CA2473990A1 CA002473990A CA2473990A CA2473990A1 CA 2473990 A1 CA2473990 A1 CA 2473990A1 CA 002473990 A CA002473990 A CA 002473990A CA 2473990 A CA2473990 A CA 2473990A CA 2473990 A1 CA2473990 A1 CA 2473990A1
Authority
CA
Canada
Prior art keywords
pipkii
beta
polypeptide
subject
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002473990A
Other languages
English (en)
French (fr)
Inventor
Lewis C. Cantley
Katja A. Lamia
Lucia Rameh
Barbara Kahn
Odile Peroni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2473990A1 publication Critical patent/CA2473990A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0325—Animal model for autoimmune diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
CA002473990A 2002-02-01 2003-02-03 Modulation of type ii.beta. phosphoinositide phosphate kinase Abandoned CA2473990A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35375802P 2002-02-01 2002-02-01
US60/353,758 2002-02-01
PCT/US2003/003065 WO2003064451A2 (en) 2002-02-01 2003-02-03 MODULATION OF TYPE IIβ PHOSPHOINOSITIDE PHOSPHATE KINASE

Publications (1)

Publication Number Publication Date
CA2473990A1 true CA2473990A1 (en) 2003-08-07

Family

ID=27663251

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002473990A Abandoned CA2473990A1 (en) 2002-02-01 2003-02-03 Modulation of type ii.beta. phosphoinositide phosphate kinase

Country Status (5)

Country Link
US (1) US20060089320A1 (cg-RX-API-DMAC10.html)
EP (1) EP1481093A4 (cg-RX-API-DMAC10.html)
JP (1) JP2005516073A (cg-RX-API-DMAC10.html)
CA (1) CA2473990A1 (cg-RX-API-DMAC10.html)
WO (1) WO2003064451A2 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012112245A1 (en) * 2011-02-14 2012-08-23 Beth Israel Deaconess Medical Center, Inc. Modulation of phosphatidylinositol-5-phosphate-4-kinase activity
WO2014068070A1 (en) 2012-10-31 2014-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291172B1 (en) * 1995-03-03 2001-09-18 Mitokor Diagnostic assay for diabetes mellitus based on mutational burden
CA2244831A1 (en) * 1996-02-02 1997-08-07 John T. Olson Method of treating diabetes and related disease states
WO2000000584A2 (en) * 1998-06-26 2000-01-06 University Of Utah Research Foundation Immobilized reagents for kinase assays
CN1321756A (zh) * 2000-04-29 2001-11-14 上海博德基因开发有限公司 一种新的多肽——人磷脂酰肌－4－磷酸－5－激酶Ⅱbeta亚基13和编码这种多肽的多核苷酸
AU2001264559A1 (en) * 2000-06-05 2001-12-17 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets

Also Published As

Publication number Publication date
EP1481093A4 (en) 2008-10-01
EP1481093A2 (en) 2004-12-01
US20060089320A1 (en) 2006-04-27
WO2003064451A3 (en) 2003-09-04
JP2005516073A (ja) 2005-06-02
WO2003064451A2 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
US11274346B2 (en) Screening method
AU2003248794B2 (en) Therapeutic methods for reducing fat deposition and treating associated conditions
US20060089320A1 (en) Modulation of type IIß phosphoinositide phosphate kinase
US20140234321A1 (en) Hunk, a snf1-related kinase essential for mammary tumor metastasis
JPH09508795A (ja) Ｍａｐ キナーゼ ホスファターゼ及びそれらをコードする核酸の生産並びに使用
AU2003210794A1 (en) Modulation of type IIbeta phosphoinositide phosphate kinase
US7214374B2 (en) 12832, a novel human kinase-like molecule and uses thereof
US20100077493A1 (en) Genes and pathways involved in bipolar disorder
US20030148394A1 (en) Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058, or 6351 molecules
JP2005511660A (ja) エネルギー恒常性の調節に関与する、ＰＴＰ１０Ｄ、Ｔｅｃタンパク質チロシンキナーゼおよびＥＤＴＰの相同性タンパク質
JP2005511660A6 (ja) エネルギー恒常性の調節に関与する、ＰＴＰ１０Ｄ、Ｔｅｃタンパク質チロシンキナーゼおよびＥＤＴＰの相同性タンパク質
CN100467601C (zh) 作为ⅱ型糖尿病靶标的pim-3激酶
EP1572227B1 (en) Pik4cb involved in the regulation of energy homeostasis
US20060015951A1 (en) Proteins involved in the regulation of energy homeostasis
US20050283842A1 (en) Mipp1 homologous nucleic acids and proteins involved in the regulation of energy homeostatis
US7157240B2 (en) MID 4460, a human tyrosine phosphatase family member and uses therefor
WO2003103704A2 (en) Proteins involved in the regulation of energy homeostasis
US20020146686A1 (en) Methods and compositions for the diagnosis and treatment of viral disease using 55092
US20050272915A1 (en) Skrp, astray, string, vacm associated with metabolic control
JP2005508618A (ja) 双極性障害に関連する核酸およびコードされるポリペプチド
WO2003084566A2 (en) Proteins involved in the regulation of energy homeostasis
WO2004016641A2 (en) Proteins involved in the regulation of energy homeostasis
JP2006514544A (ja) 新規ヒトキナーゼを使用する組成物、有機体および方法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued